Smurfit Kappa Group Total Cost of Revenue increased by 4.0% to $6.44B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.0%, from $6.08B to $6.44B. Over 2 years (FY 2022 to FY 2025), Total Cost of Revenue shows an upward trend with a 56.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.56B | $2.56B | $2.56B | $2.56B | $2.17B | $2.16B | $2.22B | $2.28B | $6.32B | $6.10B | $6.08B | $6.43B | $6.43B | $6.20B | $6.44B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -15.1% | -0.6% | +2.7% | +2.5% | +177.7% | -3.5% | -0.3% | +5.7% | +0.1% | -3.7% | +4.0% |
| YoY Change | — | — | — | — | -15.1% | -15.6% | — | — | +190.9% | +182.1% | +173.8% | +182.3% | +1.8% | +1.7% | +6.0% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| North America | $3.39B | $3.53B | $3.45B | $3.34B | $3.46B |
| Europe, MEA and APAC | $1.90B | $2.07B | $2.09B | $1.95B | $2.03B |
| LATAM | $347.00M | $357.00M | $387.00M | $372.00M | $375.00M |
| Total | $6.08B | $6.43B | $6.43B | $6.20B | $6.44B |